ISR Soars On FDA Nod For GammaTile, KMPH On Watch, Investors Believe In XLRN

Today's Daily Dose brings you news about promising trial results of Acceleron Pharma's investigational drug Luspatercept in beta-thalassemia; FDA granting Orphan Drug Designation to Cellectar Biosciences' phase I drug candidate; FDA clearance of GammaTile Therapy and its effect on IsoRay and KemPharm's encouraging results from its pivotal efficacy and safety clinical trial of KP415 in ADHD.

from RTT - Biotech https://ift.tt/2ugCowg
via IFTTT